DESCARTES-25

DESCARTES-25 is an off-the-shelf, allogeneic, RNA-engineered mesenchymal stem cell (MSC) therapy developed by Cartesian Therapeutics. It is designed to deliver two complementary antitumor proteins directly to the tumor microenvironment: a novel three-arm bispecific antibody that binds B-cell Maturation Antigen (BCMA) with femtomolar avidity and the potent antitumor cytokine interleukin-12 (IL-12). The cells are further engineered with a membrane-bound homing protein for targeted delivery. The primary indication has been relapsed/refractory multiple myeloma, but it has also been investigated in autoimmune disorders and other cancers. DESCARTES-25 represents a first-in-class approach as an off-the-shelf RNA cell therapy for cancer[1][2][3][6].

Other names

DESCARTES-25DESCARTES25DESCARTES 25